Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06049212 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06049212 · ClinicalTrials.gov record · last posted 2026-08-06

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Study acronym: TroFuse-008
StatusActive, Not Recruiting
PhasePhase 1
Started2023-10-26
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in Japanese participants with advanced solid tumors or treatment-naïve advanced or metastatic non-small cell lung cancer (NSCLC). Per protocol amendment 04, Arm 3: Pembrolizumab/Carboplatin + sacituzumab tirumotecan Combination Therapy was discontinued, and subsequently all Arm 3 procedures, recruitment, and descriptions were removed.

Protocol amendment history 1 change detected by DataLookout

2026-08-07
Primary completion pushed: 2026-06-30 → 2026-12-31
Trial Details
NCT Number NCT06049212
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Enrollment 30 participants
Start Date 2023-10-26
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-06